BioInsights - Gene therapy CMC and quality control - spotlight

CELL & GENE THERAPY INSIGHTS

Gene therapy CMC and quality control

October 2021

Download full spotlight

Are you finishing strong in cell therapy manufacturing? Tackling your final fill and finish challenges with automation

D Sethi,

A Cunningham

4 November 2021

Webinar Digest

Read more
Expression systems for viral vector production: advantages of the Sf9 baculovirus system and simple solutions to address its specific analytical challenges

Y Li,

S Kashi Ranganath

25 October 2021

Innovator Insight

Read more
Analytical toolkit for rapid formulation development of rAAV gene therapies

J Wei,

Y Cai,

J Warren

21 October 2021

Expert Insight

Read more
Challenges in AAV manufacturing: the interplay of process variations, in-process characterization, and drug product quality

D Chu,

H Acharya,

E Springfield et al.

20 October 2021

Expert Insight

Read more
Gene therapy CMC and quality control

C Bec

20 October 2021

Foreword

Read more
The Chemistry Manufacturing and Controls (CMC) section of gene therapy-based INDs: overview in a changing landscape

G Denning

17 October 2021

Expert Insight

Read more
Advancing real-time monitoring of AAV vector processes

R Legmann,

J Ferraiolo

12 October 2021

Interview

Read more
Advancing real-time monitoring of AAV vector processes

R Legmann,

J Ferraiolo

10 October 2021

Podcast

Listen now
Next steps in the evolution of AAV vector characterization technologies

E Ayuso

4 October 2021

Interview

Read more
Addressing challenges in characterizing novel AAV capsids and gene editing platform-driven therapeutics

L Drouin

1 October 2021

Interview

Read more
Considerations for developing scalable and efficient collection network processes

Lacey Anderson, Senior Manager, Collection Network Management, Be The Match BioTherapies

Sara Butler, Network Liaison, Be The Match BioTherapies

Allison Montalvo, , Program Manager, Oncology, Janssen ( A division of J&J)

28 October 2021

Webinar

Watch now
Optimization of AAV production for high-yielding and scalable GMP processes

Claire Wartel-Weill, Director of Quality and Compliance, Polyplus-transfection

Mathieu Porte, BioProduction R&D Manager, Polyplus-transfection

Bhargavi Kondragunta, Director of Internal R&D & Product Development, Catalent

George Buchman, PhD, Vice President, Pre-Clinical and Process Development, Catalent Cell & Gene Therapy

20 October 2021

Webinar

Watch now